Latest Proteasome inhibitor Stories
The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy, and support for myeloma patients, families, researchers, and physicians - today heralded the expansion of treatment options for previously untreated patients with multiple myeloma, giving patients in Canada and Europe access to drugs similar to what is available to patients in the United States.
SOUTH SAN FRANCISCO, Calif., Sept. 8 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, today announced the successful completion of a new financing round of $79 million.
Telik has announced that its small molecule proteasome inhibitor program met a preclinical development milestone by demonstrating anticancer activity in preclinical models of human leukemia.
Velcade is likely to receive EMEA approval following a positive opinion issued by the EU Committee for Medicinal Products for Human Use for use in previously untreated multiple myeloma patients.
SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Proteolix, Inc.
An anti-cancer compound derived from bacteria dwelling in ocean-bottom sediments appears in laboratory tests to be a potent killer of drug-resistant multiple myeloma cells, and potentially with less toxicity than current treatments, report Dana-Farber Cancer Institute researchers in the November issue of Cancer Cell.
Researchers eager to test laboratory findings in patient trials.